Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 63.46%170.3M | 14.69%927.19M | 46.14%584.79M | 32.68%356.01M | 2.57%104.18M | 47.47%808.4M | 21.06%400.17M | 28.00%268.32M | 26.65%101.57M | 42.52%548.19M |
Operating revenue | 63.46%170.3M | 14.69%927.19M | 46.14%584.79M | 32.68%356.01M | 2.57%104.18M | 47.47%808.4M | 21.06%400.17M | 28.00%268.32M | 26.65%101.57M | 42.52%548.19M |
Total operating cost | 62.54%150.52M | 11.03%796.47M | 39.48%493.57M | 29.28%296.57M | 2.95%92.6M | 51.29%717.33M | 26.86%353.87M | 28.92%229.39M | 19.79%89.95M | 38.27%474.13M |
Operating cost | 74.19%108.64M | 5.17%605.13M | 40.26%378.27M | 25.23%223.97M | -11.61%62.37M | 51.47%575.38M | 21.57%269.68M | 27.73%178.84M | 23.91%70.56M | 43.45%379.87M |
Operating tax surcharges | 17.30%1.49M | 30.09%6.88M | 38.18%4.59M | 31.46%3.15M | -12.30%1.27M | 33.87%5.29M | 36.85%3.32M | 75.48%2.39M | 125.29%1.45M | 17.09%3.95M |
Operating expense | 41.51%12.07M | 31.32%61.6M | 47.41%34.82M | 54.72%21.45M | 45.10%8.53M | 60.63%46.91M | 29.72%23.63M | 14.38%13.86M | 0.39%5.88M | 50.83%29.2M |
Administration expense | 28.40%16.6M | 39.95%63.78M | 27.50%41.05M | 36.39%27M | 72.08%12.93M | 41.82%45.57M | 72.86%32.19M | 62.69%19.8M | 8.64%7.51M | 9.81%32.13M |
Financial expense | -73.78%179.93K | 252.88%2.51M | 1,478.81%1.77M | 250.43%2.08M | 173.92%686.27K | -56.71%-1.64M | 66.98%-128.28K | -288.51%-1.38M | -21.10%-928.36K | -217.08%-1.05M |
-Interest expense (Financial expense) | 23.55%198.94K | 189.58%3.3M | 619.19%2.01M | 526.80%1.83M | -32.14%161.02K | -49.66%1.14M | -83.77%279.8K | -61.04%291.31K | -22.16%237.28K | -18.96%2.26M |
-Interest Income (Financial expense) | 61.01%-186.18K | 57.47%-1.78M | 59.04%-1.2M | 71.66%-898.5K | 47.88%-477.48K | -38.86%-4.2M | -59.98%-2.92M | -170.06%-3.17M | -58.37%-916.15K | -27.98%-3.02M |
Research and development | 69.25%11.54M | 23.45%56.57M | 31.36%33.07M | 19.20%18.93M | 24.59%6.82M | 52.65%45.82M | 37.95%25.17M | 25.86%15.88M | -0.33%5.47M | 19.05%30.02M |
Credit Impairment Loss | -101.51%-122.64K | 5.53%-14.6M | 32.41%-2.48M | 89.64%-461.45K | 7,268.14%8.1M | -104.51%-15.46M | -55.41%-3.67M | -429.16%-4.46M | 3.41%109.97K | -124.89%-7.56M |
Asset Impairment Loss | 54.78%-252.07K | 106.26%83.55K | -153.90%-1.56M | -694.90%-1.03M | ---557.37K | 73.52%-1.33M | 313.58%2.89M | 87.42%-129.5K | ---- | -872.16%-5.04M |
Other net revenue | ||||||||||
Invest income | -98.93%666.67K | 306.69%63.43M | 415.72%62.31M | 1,145.73%61.72M | 3,471.35%62.49M | 215.96%15.6M | 338.12%12.08M | 96.57%4.95M | 28.93%1.75M | -22.69%4.94M |
-Including: Investment income associates | ---- | -95.22%325.55K | -94.34%325.55K | -89.42%325.55K | ---- | 67.57%6.82M | 182.22%5.76M | 53.61%3.08M | 11.22%1.24M | --4.07M |
Asset deal income | ---73.89K | -107.19%-124.86K | ---- | ---- | ---- | --1.74M | ---96.23K | ---94.81K | ---- | ---- |
Other revenue | -29.10%1.52M | 28.29%9.97M | 20.53%5.84M | -9.24%3.29M | -26.87%2.15M | -22.81%7.77M | -34.45%4.84M | -40.72%3.62M | -22.16%2.94M | 26.91%10.07M |
Adjusted Items effecting operating profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---0.01 | ---- |
Operating profit | -74.31%21.52M | 90.65%189.48M | 149.12%155.33M | 187.13%122.96M | 410.09%83.77M | 29.98%99.38M | 7.45%62.35M | 11.35%42.82M | 57.28%16.42M | 43.38%76.46M |
Add:Non operating Income | --1K | 123.09%9.07M | -99.91%950.18 | -98.82%300.18 | ---- | 96.63%4.06M | -48.95%1.04M | -98.74%25.4K | --2.9K | 100.89%2.07M |
Less:Non operating expense | -68.98%19.09K | 6.64%936.14K | -29.89%446.69K | -69.53%166.73K | -42.11%61.53K | 132.52%877.89K | 69.33%637.17K | 48.84%547.19K | --106.28K | -57.23%377.55K |
Total profit | -74.31%21.5M | 92.66%197.61M | 146.80%154.89M | 190.28%122.79M | 412.94%83.71M | 31.24%102.57M | 5.13%62.76M | 5.49%42.3M | 56.29%16.32M | 46.15%78.15M |
Less:Income tax cost | -18.39%2.41M | 55.30%11.66M | 64.70%7.59M | 41.65%4.74M | 63.78%2.96M | 1.65%7.51M | -28.73%4.61M | -17.82%3.35M | 145.59%1.81M | 50.41%7.38M |
Net profit | -76.36%19.09M | 95.61%185.96M | 153.30%147.3M | 203.04%118.06M | 456.41%80.75M | 34.33%95.07M | 9.24%58.15M | 8.12%38.96M | 49.53%14.51M | 45.72%70.77M |
Net profit from continuing operation | -76.36%19.09M | 95.61%185.96M | 153.30%147.3M | 203.04%118.06M | 456.41%80.75M | 34.33%95.07M | 9.24%58.15M | 8.12%38.96M | 49.53%14.51M | 45.72%70.77M |
Less:Minority Profit | 2.50%1.36M | 9.71%5.2M | 3.68%4.03M | 6.20%2.69M | 19.41%1.33M | 4.27%4.74M | 5.33%3.89M | -0.65%2.54M | -10.42%1.11M | 15.41%4.54M |
Net profit of parent company owners | -77.68%17.73M | 100.11%180.76M | 164.03%143.26M | 216.75%115.36M | 492.69%79.42M | 36.39%90.33M | 9.53%54.26M | 8.79%36.42M | 58.32%13.4M | 48.39%66.23M |
Earning per share | ||||||||||
Basic earning per share | -77.38%0.19 | 100.00%1.9 | 164.91%1.51 | 218.42%1.21 | 500.00%0.84 | 4.40%0.95 | -18.57%0.57 | -19.15%0.38 | 16.67%0.14 | 44.44%0.91 |
Diluted earning per share | -77.38%0.19 | 100.00%1.9 | 164.91%1.51 | 218.42%1.21 | 663.64%0.84 | 4.40%0.95 | -18.57%0.57 | -19.15%0.38 | -8.33%0.11 | 44.44%0.91 |
Other composite income | 1,124.54%1.32M | -318.29%-882.9K | 663.59%627.51K | -73.43%73.61K | -40.41%108.11K | 549.60%404.46K | 123.60%82.18K | 173.32%277.04K | 170.74%181.43K | -118.13%-89.96K |
Other composite income of parent company owners | 1,124.54%1.32M | -318.29%-882.9K | 663.59%627.51K | -73.43%73.61K | -40.41%108.11K | 549.60%404.46K | 123.60%82.18K | 173.32%277.04K | 170.74%181.43K | -118.13%-89.96K |
Total composite income | -74.76%20.41M | 93.85%185.07M | 154.02%147.93M | 201.09%118.13M | 450.27%80.86M | 35.07%95.47M | 10.11%58.23M | 10.05%39.23M | 55.50%14.69M | 44.06%70.68M |
Total composite income of parent company owners | -76.05%19.05M | 98.25%179.88M | 164.79%143.89M | 214.56%115.44M | 485.56%79.53M | 37.19%90.73M | 10.47%54.34M | 10.87%36.7M | 65.48%13.58M | 46.56%66.14M |
Total composite income of minority owners | 2.50%1.36M | 9.71%5.2M | 3.68%4.03M | 6.20%2.69M | 19.41%1.33M | 4.27%4.74M | 5.33%3.89M | -0.65%2.54M | -10.42%1.11M | 15.41%4.54M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | -- | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.